← All trials
NCT05774236
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 27, 2023
- Primary completion
- May 27, 2025
- Completion date
- Sep 27, 2025
- First posted
- Mar 17, 2023
- Last posted
- Apr 25, 2023
- Enrollment
- 172
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad Complutense de MadridLead sponsor
- Universidad Complutense de MadridReponsible party - principal investigator
- Spanish Clinical Research NetworkCollaborator
- Universidad Carlos III MadridCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.